YK-012

N/A

Report date: 2026/05/02 20:00:18

Base Information

Drug NameYK-012
Drug Alias NameYK012
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAnti-CD3Anti-CD19
TargetsT cell surface glycoprotein CD3B-lymphocyte antigen CD19
Therapy Area/IndicationsLupus Erythematosus, SystemicNephrosisGlomerulonephritis, Membranous +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesExcyte Biopharma Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesExcyte Biopharma LtdWuhan Union Hospital
Inactive CompaniesN/A
Active IndicationsLupus Erythematosus, SystemicNephrosisGlomerulonephritis, Membranous +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A